ALOX15B is expressed in human monocyte-derived macrophages, and it is believed that the progression of cytogenetically normal AML could be a dysfunction of immune cells in the bone marrow microenvironment (82, 83), directly connecting it to AML progression and nominating it as a possible mechanism of age-related AML therapeutic intervention. Here, ALOX15B is linked to acute myeloid leukemia.